JOINT (JYNT) Company Report

The Joint Corp. signed an Asset Purchase Agreement (APA) for the sale of 22 corporate-owned or managed clinics to three buying groups for $1.5 million.
These clinics are located in Virginia, North Carolina, South Carolina, and Georgia, with buyers expected to assume operations in mid-December 2025.
The company also delivered a notice to terminate the APA for 45 clinics in Southern California, an agreement that was originally signed on November 2, 2025.

3 days ago

JYNT Announces Q3 2025 Financial Results and Revised 2025 Guidance

JYNT

Earnings

Guidance Update

Share Buyback

JYNT reported a 36% increase in Q3 2025 consolidated Adjusted EBITDA over Q3 2024, reaching $3.3 million. However, Q3 2025 system-wide sales decreased by (1.5)% and comparable sales decreased by (2.0)%.
The company revised its 2025 guidance, with current projections for system-wide sales between $530 million and $534 million, comparable sales between (1)% and 0%, and new franchised clinic openings between 30 and 35.
JYNT is focused on becoming a pure-play franchisor, with 92% of its portfolio franchised and potential buyers identified for remaining corporate clinics.
The balance sheet remains strong with $29.7 million in unrestricted cash and no debt as of September 30, 2025. The company also purchased 540,000 shares for $5 million and authorized up to another $12 million for stock repurchases.
JYNT implemented new accounting adjustments to consolidate the full operations of professional corporations (PCs), which will increase revenue and G&A expenses by an identical amount, with no impact on the bottom line except for deferred revenue from treatment packages and wellness plans.

Nov 6, 2025, 10:00 PM

JYNT Reports Q3 2025 Results, Updates Guidance, and Advances Refranchising Efforts

JYNT

Earnings

Guidance Update

Share Buyback

The Joint Corporation reported Q3 2025 revenue from continuing operations increased 6% to $13.4 million and consolidated adjusted EBITDA grew 36% to $3.3 million, despite system-wide sales decreasing 1.5% to $127 million and comp sales declining 2% compared to Q3 2024.
The company is progressing towards becoming a pure-play franchisor, with an initial agreement to sell 45 corporate clinics for $4.5 million and ongoing negotiations for 33 additional clinics.
Strategic initiatives include a new national marketing campaign focused on pain relief, funded by a reallocation of franchisee ad spend, and a three-tiered pricing pilot for wellness plans launched in November.
JYNT revised its full-year 2025 guidance, projecting system-wide sales between $530-$534 million and comp sales in the range of -1% to flat, while maintaining consolidated adjusted EBITDA guidance of $10.8-$11.8 million.
Liquidity remains strong with $29.7 million in unrestricted cash as of September 30, 2025, and the board authorized an additional $12 million for stock repurchases following $5 million in buybacks during and after Q3 2025.

Nov 6, 2025, 10:00 PM

The Joint Corp. Reports Q3 2025 Financial Results and Updates Guidance

JYNT

Earnings

Share Buyback

Guidance Update

The Joint Corp. reported Q3 2025 revenue of $13.4 million, a 6% increase compared to Q3 2024, with consolidated net income of $855,000 (compared to a net loss of $3.2 million in Q3 2024) and Adjusted EBITDA for consolidated operations increasing 36% to $3.3 million.
The company's Board of Directors authorized an additional $12 million for its stock repurchase program, extending the authorization through November 4, 2027, after repurchasing 540,000 shares for $5 million between August and October.
System-wide sales for Q3 2025 declined 1.5% to $127.3 million, and comp sales were (2.0)%.
The 2025 guidance for system-wide sales was revised to a range of $530 million to $534 million and comp sales to (1)% to 0%, while consolidated Adjusted EBITDA guidance remained at $10.8 million to $11.8 million.

Nov 6, 2025, 9:09 PM

The Joint Corp. Authorizes Additional $12 Million for Stock Repurchase Program

JYNT

Share Buyback

The Joint Corp. board of directors has authorized an additional $12 million for its stock repurchase program.
This authorization follows the completion of an initial $5 million tranche, which resulted in the buyback of 540,000 shares between August and October.
CEO Sanjiv Razdan stated that this action reinforces the company's commitment to disciplined capital allocation and its belief that the current share price does not fully recognize its long-term valuation.

Nov 5, 2025, 12:05 PM